Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts

International Journal of Antimicrobial Agents

Volumn 17, Issue 2, 2001, Pages 81-91

  Bastert, J ^a   Schaller, M ^c   Korting, H C ^c   Evans, E G V ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c NONE

Author keywords

Antimicrobial resistance; Antimycotics; Immunoreconstitution; Targets

Indexed keywords

ALLYLAMINE DERIVATIVE; AMOROLFINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOFURAZAN DERIVATIVE; CICLOPIROXOLAMINE; FLUCONAZOLE; FLUCYTOSINE; FLUOROPYRIMIDINE DERIVATIVE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MORPHOLINE DERIVATIVE; NIKKOMYCIN; PEPSTATIN; POLYENE; PYRROLE DERIVATIVE; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

CANDIDA ALBICANS; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; IMMUNE DEFICIENCY; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES;

EID: 0035139912     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00323-X     Document Type: Review

References (101)

1. Fungal burn wound infection, a 10-year experience
2. Candidiasis: implications for intensivists and pulmonologists
3. Mechanisms and clinical impact of antifungal drug resistance
4. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
5. The role of immunoreconstitution in the management of refractory opportunistic fungal infections
6. Jenkinson HF. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance
7. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS-patients caused by defective sterol 5, 6-desaturation
8. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
9. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve multidrug transporters
10. Discovery and development of new systemic antifungals
11. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene
12. Amphotericin B: new life for an old drug
13. New approaches to antifungal chemotherapy
14. Synthesis and antifungal selectivity of new derivatives of amphotericin B modified at the C-13 position
15. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
16. Altered P450 activity associated with direct selection for fungal azole resistance
17. Antifungal resistance trends towards the year 2000
18. In vitro studies of two triazole antifungal agents (voriconazole (UK-109, 496) and fluconazole) against Candida species
19. New directions in antifungal therapy
20. Antifungals targeted to the cell wall
21. Effects of squalene epoxidase inhibitors on Candida albicans
22. Antifungal agents: chemotherapeutic targets and immunologic strategies
23. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses
24. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium
25. Key issues concerning fungistatic versus fungicidal drugs
26. New mechanisms of action with fungicidal antifungals
27. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections
28. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole
29. The future of antifungal therapy
30. Antifungal agents in the 1990s. Current status and future developments
31. Antifungal drug resistance in pathogenic fungi
32. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo
33. Treatment of infection due to Pneumocystis carinii
34. Pradimicin Q, a new pradimicin aglycone, with α-glucosidase inhibitory activity
35. Synergic inhibitory activity of amphotericin-B and interferon against intracellular Cryptoccocus neoformans in murine macrophages
36. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs
37. Synthesis and biological activities of some 3, 6-disubstituted thiazolo (3, 2-b) (1, 2, 4) triazoles
38. Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections
39. Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays
40. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp
41. T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations
42. Antifungal triazole alcohols: a comparative analysis of structure-activity, structure-therapeutic index relationships using the Multiple Computer-Automated Structure Evaluation (Multi-CASE) methodology
43. Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk
44. Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae - a review
45. The hydroxypyridones: a class of antimycotics of its own
46. The mechanism of calprotectin's candidastatic activity appears to involve zinc chelation
47. Inhibition of Candida albicans adhesiveness to human buccal and vaginal cells by sub-inhibitory concentrations of rilopirox
48. Topoisomerase I is essential in Cryptococcus neoformans: role in pathobiology and as an antifungal target
49. Antifungal properties and target evaluation of three putative bacterial histidine kinase inhibitors
50. In vitro antifungal activities and in vivo efficacies of 1, 3-β-D-glucan synthesis inhibitors L-671, 329, L-646, 991, tetrahydroechinocandin B and L-687, 781, a papulacandin
51. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373
52. Echinocandins and pneumocandins - a new antifungal class with a novel mode of action
53. Collaboration of human phagozytes with LY 303366 for antifungal activity against Aspergillus fumigatus
54. Echinocandin lipopeptide antifungal agents: new agents and recent chemical modification studies
55. The echinocandins: antifungals targeted to the fungal cell wall
56. Antibiotics that inhibit fungal cell wall development
57. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB
58. Identification of the FKS1 gene of Candida albicans as the essential target of 1, 3-β-D-glucan synthase inhibitors
59. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1, 3-β-D-glucan synthase
60. Lipopeptide inhibitors of fungal glucan synthase
61. Increased antifungal activity of L-733, 560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis
62. Antifungal activity of LY295337 in vitro against clinical isolates of Candida spp
63. Comparison of the in vitro activities of the echinocandin LY 303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
64. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY 303366, and other antifungal agents
65. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates
66. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species
67. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp
68. Development of a plasma high-performance liquid chromatographic assay for LY 303366, a lipopeptide antifungal agent, and its application in a dog pharmacokinetic study
69. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species
70. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, L-731373 with mouse models of disseminated aspergillosis, candidiasis and cryptococcosis
71. In vitro activity of a new pneumocandin antifungal agent, L-733560 against azole-susceptible and -resistant Candida and Torulopsis species
72. Pradimicins: a novel class of broad-spectrum antifungal compounds
73. In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various Candida spp
74. Nikkomycin Z supersensitivity of an echinocandin-resistant mutant of Saccharomyces cerevisiae
75. Nikkomycin Z is a specific inhibitor of Saccharomyces cerevisiae chitin synthase isozyme Chs3 in vitro and in vivo
76. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184
77. BMS-181184, a new pradimicin derivative. Screening, taxonomy, directed biosynthesis, isolation and characterization
78. Pradimicins FS and FB, new pradimicin analogs: directed production, structures and biological activities
79. In vivo expression and localization of Candida albicans secreted aspartyl proteinases during oral candidiasis in HIV-infected patients
80. Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis
81. Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in a patient samples from the oral cavity
82. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents
83. Candida albicans secreted aspartyl proteinases
84. Candida species and virulence
85. Increased expression of Candida albicans secretory proteinase, a virulence factor, in isolates from human immunodeficiency virus-positive patients
86. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients
87. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study
88. The significance of secretory and structure-associated proteases of Aspergillus fumigatus for the pathogenesis of invasive aspergillosis
89. Purification and characterization of an extracellular aspartic proteinase from Aspergillus fumigatus
90. Molecular cloning and sequencing of the gene encoding an extracellular aspartic proteinase from Aspergillus fumigatus
91. Proteinase
92. The yeast plasma membrane proton pumping ATPase is a viable antifungal target. I. Effects of the cysteine-modifying reagent omeprazole
93. Targeting the fungal plasma membrane proton pump
94. Fungal plasma membrane proton pumps as promising new antifungal targets
95. New systematically active antimycotics from the beta-blocker category
96. Discovery, biosynthesis and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase
97. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685, 818 are toxic to Cryptococcus neoformans by inhibition of a common target protein
98. Fusaricide, a new cytotoxic N-hydroxypyridone from Fusarium spp
99. A novel big defensin identified in horseshoe crab hemocytes: isolation, amino acid sequence and antibacterial activity
100. The crystal structure of a major secreted aspartic proteinase from Candida albicans incomplexes with two inhibitors